Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) and Bullfrog AI (NASDAQ:BFRG – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.
Profitability
This table compares Maravai LifeSciences and Bullfrog AI’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Maravai LifeSciences | -37.07% | -15.70% | -8.17% |
| Bullfrog AI | N/A | -150.36% | -127.98% |
Analyst Recommendations
This is a summary of current ratings for Maravai LifeSciences and Bullfrog AI, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Maravai LifeSciences | 1 | 1 | 2 | 0 | 2.25 |
| Bullfrog AI | 1 | 1 | 0 | 0 | 1.50 |
Insider & Institutional Ownership
50.2% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 14.7% of Bullfrog AI shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Risk and Volatility
Maravai LifeSciences has a beta of 0.6, meaning that its share price is 40% less volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of -2.71, meaning that its share price is 371% less volatile than the S&P 500.
Valuation & Earnings
This table compares Maravai LifeSciences and Bullfrog AI”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Maravai LifeSciences | $208.78 million | 9.52 | -$130.77 million | ($0.52) | -14.71 |
| Bullfrog AI | $120,000.00 | 100.10 | -$6.50 million | ($0.46) | -1.41 |
Bullfrog AI has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.
Summary
Maravai LifeSciences beats Bullfrog AI on 8 of the 14 factors compared between the two stocks.
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.
About Bullfrog AI
Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
